Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

MGI Q4'22: Attractive risk-reward ratio

Verve Group

MGI’s Q4 figures came in at the top end of the guidance beating our estimates. At the current market price MGI’s valuation is still rather low. Analyst Anton Damstén summarizes 2022, business model and risks.

Contents:
00:00 Introduction
00:23 MGI in a nutshell
01:40 Q4 and 2022
05:30 Strategy and business model
10:28 Growth drivers
14:06 Risks
19:22 Valuation and recommendation

Read the latest research, published 2023-03-01: MGI: Risk-to-reward ratio still attractive

Read the extensive research, published 2022-12-12: An overlooked and undervalued platform company

Stay up to date
Analyst Interviews

Seneste videoer

Orion as an Investment | Life Science Night Dec. 9, 2025
13.12.2025, 12.50 Orion
AKTIER MED FRIIS - UGE 50 2025
12.12.2025, 12.00
HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier
12.12.2025, 09.27 Novo Nordisk
A sit-down with CEO Remco Westermann
12.12.2025, 09.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025, 11.00 Aiforia Technologies
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.